HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Behn, D. Articles by Potter, M. J. Search for Related Content PubMed PubMed Citation Articles by Behn, D. Articles by Potter, M. J.

Sildenafil-Mediated Reduction in Retinal Function in Heterozygous Mice Lacking the -Subunit of Phosphodiesterase

From the Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
PURPOSE. Retinitis pigmentosa (RP) is a common inherited degenerative retinal disease that has many causes including mutations in the genes coding for cyclic guanosine monophosphate (cGMP) phosphodiesterase 6 (PDE6). Sildenafil (Viagra; Pfizer Pharmaceuticals, New York, NY), a widely used medication for erectile dysfunction, is a specific inhibitor of PDE, with the potential to affect PDE6 in the retina. The purpose of this study was to investigate the retinal effects of sildenafil on knockout mice heterozygous for a mutation causing absence of the subunit of rod PDE6 (Pdeg^tm1/+).

METHODS. Wild-type mice and Pdeg^tm1/+ mice were subjected to electroretinography (ERG) 1 hour after exposure to one of three treatments: 1) no drug, 2) an intraperitoneal injection of sildenafil at 2 times the equivalent maximal daily recommended dosage for humans, or 3) 10 times this dosage. Control ERGs were also obtained to evaluate the reversibility of changes in retinal function after sildenafil treatment. A minimum of 48 hours elapsed between electroretinogram (ERG) recordings for drug washout and animal recovery.

RESULTS. ERGs of the Pdeg^tm1/+ mice treated with sildenafil showed a reversible, dose-dependent decrease in a- and b-wave amplitudes. Wild-type mice treated with sildenafil did not show significant differences in either a- or b-wave amplitudes compared with untreated control animals.

CONCLUSIONS. These findings suggest that sildenafil has a significant impact on retinal function in Pdeg^tm1/+ mice and may have implications in human carriers of RP. In addition, extension of these results in other model systems could be useful in understanding the mechanisms of RP and other forms of retinal degeneration.

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Retinitis pigmentosa (RP) is a group of inherited retinal diseases that causes degeneration of the photoreceptors and often progresses to blindness. Affected individuals experience night blindness, loss of peripheral vision, and decreased central vision progressing over many years.¹ Despite an explosion of information on the molecular biology of RP, an effective treatment for most patients remains elusive. Many RP mutations have been identified in humans, including some in the cyclic guanosine monophosphate (cGMP) phosphodiesterase 6 (PDE6) genes.^{2 3 4 5 6} PDE6 is a central enzyme in the retinal phototransduction cascade, and its catalytic site has a 45% to 48% sequence identity with PDE type 5 (PDE5),⁷ an isoenzyme found in vascular smooth muscle in the corpus cavernosum.^{8 9 10} As would be expected, their sequence homology leads to similarities in responses to inhibitors.¹⁰

Sildenafil (Viagra; Pfizer Pharmaceuticals, New York, NY) is a PDE5 inhibitor in wide use for the treatment of erectile dysfunction.^{8 9} It is known to increase the level of cGMP, and ultimately increases penile response to sexual stimulation.¹¹ Sildenafil preferentially inhibits PDE5 more than PDE6, with a relative mean inhibitory concentration of 1:10.¹⁰ The potential therefore exists for this drug to alter retinal function, not only in normal subjects, but also in patients with PDE6 gene mutations such as in some forms of RP.

Visual side effects of sildenafil in humans have been reported to include the temporary occurrence of blue-tinged or hazy vision and an increased sensitivity to light.^{12 13 14 15 16} These phenomena increase with dosage, with the incidence approaching 50% if recommended dosages are exceeded.¹⁷ Studies evaluating retinal function in humans by electroretinography have noted small transient changes to the electroretinogram (ERG).^{18 19 20 21 22} Such investigations have focused on normal subjects rather than those with underlying retinal diseases. Little information is therefore available on the potential side effects of sildenafil in patients with frank RP or in carriers.

The PDE enzyme consists of an , a ß, and two subunits. The first two subunits are catalytic, whereas the latter perform an inhibitory function. Pdeg^tm1/Pdeg^tm1 gene knockout mice have been well-characterized recently.^{23 24 25 26} These homozygotes do not possess the -subunit of PDE6, resulting in low enzyme activity, leading to elevated levels of cGMP in the retina. High cGMP concentrations are thought to be the initiating factor that triggers the degeneration of the photoreceptor cells. The Pdeg^tm1/Pdeg^tm1 homozygotes have been shown to have retinal degeneration analogous to RP in humans with known PDE mutations. Conversely, heterozygous (Pdeg^tm1/+) mice have been shown to have normal retinal electrophysiology and histology, similar to most autosomal recessive human RP carriers. This animal model makes it possible to test the effects of various pharmacologic agents on the retina in vivo, with potential application to the understanding and treatment of human RP. The goal of this study was to quantify the effects of sildenafil on retinal function in heterozygous Pdeg^tm1/+ mice using electroretinography.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Mice
All procedures concerning animals in this study were approved by the Animal Care Committee at the University of British Columbia and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Founder homozygous Pdeg^tm1/Pdeg^tm1 mice were obtained from Columbia University (New York, NY) and crossed with wild-type C57BL/6 (+/+) mice (Jackson Laboratories, Bar Harbor, ME) to produce heterozygous Pdeg^tm1/+ mice. All matings and subsequent offspring were carefully monitored in our animal care facility (Jack Bell Research Building, Vancouver, Canada). Mice were reared in a 12-hour dark–light cycle, which produced an ambient light level between 60 and 100 lux in the cages. All experiments were performed between postnatal day (P)28 and P49.

Sildenafil
Using sterile technique, 100-mg tablets of sildenafil were pulverized and then solubilized with 0.9% NaCl. The subsequent solution was then filtered with a Sterivex-GS 0.22-µm filter unit (Millipore, Bedford, MA) and stored in a sterile container at 4°C. The sildenafil (3.5 mg/ml) solution was warmed to room temperature before treatment.

Electroretinography
Three groups of mice were tested. Each mouse in group I (+/+ wild-type) underwent ERG recordings in the following order at three time points: 1) before sildenafil treatment (n = 11), 2) 1 hour after an intraperitoneal injection of sildenafil at 2 times (2x; 2.9 mg/kg) the equivalent maximum dose by weight recommended for a 70-kg human (n = 11), and 3) 1 hour after an intraperitoneal injection of sildenafil at 10 times (10x; 14.3 mg/kg) the equivalent maximum dose by weight recommended for a 70-kg human (n = 7).

Each mouse in group II (Pdeg^tm1/+ heterozygotes) underwent ERG recordings at three time points: 1) before sildenafil treatment (n = 12), 2) 1 hour after an intraperitoneal injection of sildenafil at the 2x dose (n = 11), and 3) 1 hour after an intraperitoneal injection of sildenafil at the 10x dose (n = 12). Group II, Pdeg^tm1/+ heterozygous mice (n = 7) were also retested without sildenafil treatment, after the 10x treatment to evaluate the potential reversibility of the effect of sildenafil treatment on the ERGs.

The initial recordings obtained from groups I and II were between P28 and P36. A minimum of 48-hours was maintained between all successive ERG recordings to ensure drug washout and to allow animal recovery.

Each mouse in group III (Pdeg^tm1/Pdeg^tm1 homozygotes) underwent ERG recordings at a single time point (P49) without sildenafil treatment (n = 5) as a control to verify the retinal degeneration previously reported at P56.²³

All ERG recordings were performed by the same investigator (DB), according to a similar method previously reported.²⁷ Before each recording session, all mice were dark adapted for a minimum of 12 hours. Under dim illumination, mice receiving treatment were given an intraperitoneal injection of 2x and of 10x sildenafil 1 hour before ERG recordings. Just before recording, all mice were anesthetized with an intramuscular injection of a ketamine (150 mg/kg) and xylazine (7.5 mg/kg) mixture. The pupils were dilated (1% cyclopentolate hydrochloride), and a DTL electrode (X-Static silver-coated conductive nylon yarn; Sauquoit, Scranton, PA) was placed on the corneal surface, which was kept moist with 0.5% methylcellulose. A reference electrode was placed in the mouth (E5 disc electrode; Grass, Quincy, MA), and a ground electrode (E2 subdermal electrode; Grass) was positioned in the tail, after topical anesthetic (1% lidocaine jelly) application to minimize any discomfort. Mice were positioned in front of a Ganzfeld dome on a warmed stage to minimize body heat loss. Scotopic intensity response functions were generated with flashes of white light emitted by a visual electrodiagnostic system (model UTAS E-2000; LKC, Gaithersburg, MD) 20 µsec in duration, starting with a -4.3 log [candelas]cd/m^-2 per second stimulus and progressing to the brightest flash at 0.5 log cd/m^-2 per second in 0.8-log-unit steps. Each response represented an average of two to five flashes, depending on the intensity of the stimulus. To avoid the conditioning effect previously reported to alter dark-adapted ERGs, a minimum interstimulus interval of 15 seconds was maintained.^{28 29} All responses were amplified, filtered (low [0.5 Hz] and high [1500 Hz] cutoff), and averaged (LKC software). For ERG waveform analysis, the a-wave was measured from baseline to the first negative trough of the ERG response, and the b-wave amplitude was measured from the a-wave trough to the most positive peak of the response. At flash intensities that failed to evoke an a-wave, the b-wave was measured from baseline to the most positive peak. All implicit times were measure from flash onset to the corresponding a- and b-wave amplitudes. Statistical significance was determined using analysis of variance (ANOVA).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Decreased Retinal Function
We recorded dark-adapted ERGs from Pdeg^tm1/+ mice and wild-type (+/+) mice 1 hour after they were treated with 2 and 10 times the maximum equivalent therapeutic dose of sildenafil per unit mass recommended for humans. ERG recordings from Pdeg^tm1/+ heterozygotes and +/+ wild-type mice obtained before sildenafil treatment were used as control animals. The average a- and b-wave amplitudes (Fig. 1B 1D) obtained from 2x-treated Pdeg^tm1/+ mice were significantly (P < 0.001) reduced to 121 ± 19 µV (47% ± 6.8% of the control value) and 473 ± 67 µV (55% ± 8.1% of control value), respectively, at the brightest stimulus intensity (0.5 log cd/m^-2 per second). When 2x-treated Pdeg^tm1/+ mice were exposed to stimuli eliciting a pure rod response (stimulus of -1.9 log cd/m^-2 per second), the average b-wave amplitude reached 206 ± 37 µV representing 49% ± 7.8% of the b-wave amplitude recorded from untreated control animals at the same intensity. Thus, ERGs from the 2x Pdeg^tm1/+ group (Fig. 2B) exhibited a marked decrease in amplitudes compared with untreated control animals (Fig. 2A) . Implicit times of the a- and b-waves of 2x-treated mice were not significantly different from control animals at either the pure rod response (b-wave P > 0.05) or at the brightest stimulus intensity (a-wave and b-wave P > 0.05).

View larger version (26K): [in this window] [in a new window]   Figure 1. Summary of scotopic intensity response functions obtained from untreated and sildenafil-treated wild type (A, C) and heterozygous Pdegtm1/+ (B, D) mice. (A, B) b-Wave and (C, D) a-wave amplitudes obtained in untreated conditions and after 2x and 10x sildenafil treatment. Sildenafil had little effect on ERG amplitudes in wild-type (+/+) mice but appeared to have a dose-dependent reduction in a-wave and b-wave amplitudes in heterozygous (Pdegtm1/+) mice. All symbols represent the mean values recorded at that stimulus. Bars, SEM.

View larger version (17K): [in this window] [in a new window]   Figure 2. Representative scotopic ERG intensity response functions obtained from the left eye of the same heterozygous (Pdegtm1/+) mouse showing (A) untreated control conditions, (B) response to 2x and (C) 10x sildenafil treatments, and (D) retesting after washout of 2x and 10x sildenafil treatments. Mice treated with sildenafil (B, C) showed a dose-dependent decrease in a-wave (arrowhead) and b-wave amplitudes in contrast to untreated (A) values. ERG responses illustrated in the posttreatment retested mouse (D) showed little difference when compared with its control (A). A minimum 48-hour period for recovery and drug washout was maintained between each recording session. Arrow: Flash onset.

Reversibility
The reversibility of the acute effects of sildenafil was determined by retesting Pdeg^tm1/+ mice that had previously received 2x and 10x sildenafil treatment but had been given at least a 48-hour period for recovery and drug washout. No significant differences in scotopic amplitudes or implicit times were observed at either the dimmest (-1.9 log cd/m^-2 per second) or brightest (0.5 log cd/m^-2 per second) stimulus intensities between the retested eyes and the responses previously obtained from the untreated Pdeg^tm1/+ control animals (P > 0.05; Fig. 2D ).

Sildenafil Effects on Retinal Function in Wild-Type (+/+) Mice
We measured ERGs in wild-type (+/+) mice 1 hour after intraperitoneal injections of 2x and 10x sildenafil (Figs. 1A 1C) . Neither treatment (Figs. 3B 3C) produced differences in a- and b-wave amplitudes (P > 0.05) compared with untreated control animals. At the two brightest stimuli, however, the b-wave amplitudes displayed a trend toward higher amplitudes with increasing sildenafil dosage. The a- and b-wave implicit times of 2x- and 10x-treated wild-type (+/+) mice showed no differences (P > 0.05) when compared with those in untreated control animals.

View larger version (16K): [in this window] [in a new window]   Figure 3. Representative scotopic ERG intensity response functions obtained from the left eye of one wild-type (+/+) mouse showing (A) untreated control conditions (B) after 2x and (C) 10x sildenafil treatments. When different treatments were compared at the same stimulus, the a-wave (arrowhead) and b-wave amplitudes showed minor variations. A minimum 48-hour period for recovery and drug washout was maintained between each recording condition. (D) Representative scotopic ERG intensity response functions obtained from an untreated (-/-) control mouse on postnatal day 49 were not measurable. Arrow: Flash onset.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Our study shows that sildenafil can markedly decrease retinal function in knockout mice heterozygous for the PDE6 -subunit gene mutation (Pdeg^tm1/+) with as little as 2x the maximum equivalent dose recommended for humans. Further decreases to both a- and b-wave amplitudes, with concurrent delays in implicit times, were observed in Pdeg^tm1/+ mice treated with 10x sildenafil. This dose-dependent decrease was not observed in wild-type (+/+) control animals.

We were surprised to note that wild-type (+/+) mice had a subtle dose-dependent augmentation of ERG amplitudes at brighter stimuli with sildenafil treatment. These results are in contrast to the known action of sildenafil as an inhibitor of PDE6. A similar effect was reported in wild-type dogs receiving increasing doses of sildenafil.^{31 32} However, a moderate decline in the ERG was noted in these animals when the dosage reached 10x the maximum equivalent dose recommended for humans, a result not observed in the present study. Studies of nonspecific PDE inhibitors in cats demonstrated that lower doses slightly increase the amplitude of the rod b-wave, whereas diminished amplitudes were observed at higher doses.³³ Because a given concentration of sildenafil inhibits PDE6 10 times less than PDE5,¹⁰ the 2x- and 10x-treated wild-type (+/+) mice may have responded in a relatively low-dose fashion, exhibiting the ERG enhancement seen at lower doses of nonspecific PDE inhibitors. This low-dose response may also be responsible for the temporary side effects, such as increased sensitivity to light, that have been noted in patients taking sildenafil.¹²

The heterozygous PDE6 -subunit knockout mutation probably leads to a decrease in functional PDE6, creating enhanced susceptibility to the inhibitory effects of sildenafil. Higher levels of cGMP resulting from this effect may clamp the membrane potential at a depolarized voltage resulting in a partial blockage of the phototransduction cascade. Increasing the dosages of sildenafil would be expected to produce further reductions in PDE6 activity and retinal function, as we observed. Accordingly, heterozygous Pdeg^tm1/+ mice receiving 2x and 10x sildenafil had diminished retinal function; whereas similarly treated wild-type (+/+) mice did not. Although other investigators have studied the effects of phototransduction cascade inhibitors, so far as we are aware, we are the first to report that a specific inhibitor of PDE decreases retinal function in a model of retinal degeneration.

Although our study focused on the inhibitory effects of sildenafil, we also evaluated short-term reversibility of these effects on retinal function in heterozygous Pdeg^tm1/+ mice. A minimum 48-hour (36–120 half-lives) washout and recovery period was used before testing for reversibility,³⁰ and it is therefore unlikely that any drug remained at the time of retesting. Sildenafil’s impact on retinal function in Pdeg^tm1/+ mice appeared to be temporary, although there are no long-term data. One-year ocular toxicity studies involving wild-type dogs receiving high doses of sildenafil have reported similar results,³¹ but toxicity studies have not been performed on animals that are carriers of retinal degenerations. Repeated exposure to sildenafil in carriers may result in chronically elevated levels of cGMP, placing them at an increased risk for retinal toxicity. Long-term studies would be helpful to investigate this concern further.

We found no appreciable rod function in untreated Pdeg^tm1/Pdeg^tm1 knockout mice at 7 weeks after birth. It has been reported previously that these homozygous Pdeg^tm1/Pdeg^tm1 mice have reduced PDE6 activity, reduced electrophysiologic responses, and histologic evidence of retinal degeneration analogous to that found in RP.²⁴ Diminished levels of PDE6 are known to increase cGMP in Pdeg^tm1/Pdeg^tm1 mice, and high cGMP levels are in turn known to be toxic to the retina,^{34 35 36} explaining both the electrophysiologic and histologic findings.²³ Our observations of extinguished ERGs in the homozygous Pdeg^tm1/Pdeg^tm1 mice are in keeping with this mechanism. Given that the PDE -subunit deletion of the Pdeg^tm1/Pdeg^tm1 mouse effectively reproduces the same retinal degeneration observed in the PDE ß-subunit mutant rd/rd, presumably the implications for heterozygous Pdeg^tm1/+ ß-subunit carriers would be similar to the carriers previously described in the rd1 mouse.²³

At least 1 in 50 people worldwide is a carrier of RP.³⁷ Most carriers have normal visual function and ERGs,³⁸ but their risk for potential retinal toxicity from PDE inhibitors is presently unknown. Recent human studies found no evidence of ocular toxicity, aside from transient visual disturbances in patients taking sildenafil.^{15 16 22 39 40} However, these studies have either excluded subjects with known visual problems, or have been unlikely to include a sufficient number of RP carriers to study this important subpopulation. Thus, the transient and potential long-term effect of sildenafil on visual function may not be fully appreciated at this time.

Although our understanding of RP has progressed rapidly, only one half of known genes responsible for this disease have been characterized⁴¹ (summarized on Retnet at http://www.sph.uth.tmc.edu/Retnet/home.htm; provided by the University of Houston–Texas Health Science Center). PDE - and ß-subunit mutations have been characterized in individuals with RP^{2 3 4 5 6} ; however, -subunit mutations have not yet been identified in humans.⁴² Whether people heterozygous or homozygous for - and ß-subunit mutations are susceptible to changes in retinal function from sildenafil in a fashion analogous to the Pdeg^tm1/+ heterozygous mice remains to be seen. Moreover, because PDE6 mutations comprise a modest 3% to 4.5% of cases of autosomal recessive RP in humans,⁵ an important issue is to determine whether mutations in other genes leading to retinal degenerations lead to the same potential susceptibility. We look forward to extension of our results in other model systems to further elucidate the physiologic risks to people heterozygous for RP.

	Acknowledgements

 
The authors thank Peter Gouras and Stephen Tsang for providing Pdeg^tm1/Pdeg^tm1 mice, Pierre Lachapelle for critically reading the manuscript, and Ann Lee for technical assistance.

	Footnotes

 
Submitted for publication July 19, 2000; revised October 2, 2000; accepted October 6, 2000.

Commercial relationships policy: N.

Corresponding author: Michael J. Potter, Department of Ophthalmology, University of British Columbia, 2550 Willow Street, Vancouver, BC, Canada V5Z 3N9. mpotter{at}interchange.ubc.ca

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Heckenlively, JR. (1988) Retinitis Pigmentosa ,1-24 JB Lippincott Philadelphia.
2. McLaughlin, ME, Sandberg, MA, Berson, EL, Dryja, TP (1993) Recessive mutations in the gene encoding the ß-subunit of rod phosphodiesterase in patients with retinitis pigmentosa Nat Genet 4,130-134[Medline][Order article via Infotrieve]
3. Danciger, M, Blaney, J, Gao, YQ, et al (1995) Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa Genomics 30,1-71[Medline][Order article via Infotrieve]
4. Huang, SH, Pittler, SJ, Huang, X, Oliveira, L, Berson, EL, Dryja, TP (1995) Autosomal recessive retinitis pigmentosa caused by mutations in the -subunit of rod cGMP phosphodiesterase Nat Genet 11,468-471[Medline][Order article via Infotrieve]
5. McLaughlin, ME, Ehrhart, TL, Berson, EL, Dryja, TP (1995) Mutation spectrum of the gene encoding the ß subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa Proc Natl Acad Sci USA 92,3249-3253[Abstract/Free Full Text]
6. Dryja, TP, Rucinski, ED, Chen, SH, Berson, EL (1999) Frequency of mutations in the gene encoding the subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa Invest Ophthalmol Vis Sci 40,1859-1865[Abstract/Free Full Text]
7. McAllister–Lucas, L, Sonnenburg, WK, Kadlecek, A, et al (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone J Biol Chem 268,22863-22873[Abstract/Free Full Text]
8. Boolell, M, Allen, MJ, Ballard, SA, et al (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction Int J Impot Res 8,47-52[Medline][Order article via Infotrieve]
9. Moreland, RB, Goldstein, I, Traish, A. (1998) Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells Life Sci 62,L309-PL318
10. Ballard, SA, Gingell, CJ, Tang, K, Turner, LA, Price, ME, Naylor, AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes J Urol 159,2164-2171[Medline][Order article via Infotrieve]
11. Walman, SA, Murad, F. (1987) Cyclic GMP synthesis and function Pharmacol Rev 39,163-196[Medline][Order article via Infotrieve]
12. . Center for Drug Evaluation and Research (1998) A double-blind, randomized, placebo-controlled, four-period crossover study to assess the effect of orally-administered sildenafil (50, 100, and 200 mg) on visual function in healthy male volunteers: study 148–223 Viagra (Sildenafil): Joint Clinical Review for NDA-20-895 Center for Drug Evaluation and Research, Food and Drug Administration Washington, DC.
13. . Center for Drug Evaluation and Research (1998) A randomized, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral tablet dose of sildenafil (200 mg) on visual function (electroretinogram, photostress, visual field and color discrimination tests) in healthy male volunteers and patients with diabetic retinopathy: study 148–232 Viagra (Sildenafil): Joint Clinical Review for NDA-20-895 Center for Drug Evaluation and Research, Food and Drug Administration Washington, DC.
14. Laties, A, Ellis, P, Mollon, JD (1999) The effects of sildenafil citrate (Viagra) on color discrimination in volunteers and patients with erectile dysfunction [ARVO Abstracts] Invest Ophthalmol Vis Sci 40(4),S693Abstract nr 3660.
15. Morales, A, Gingell, C, Collins, M, Wicker, PA, Osterloh, IH (1998) Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction Int J Impot Res 10,69-74[Medline][Order article via Infotrieve]
16. Goldstein, H, Lue, TF, Padma–Nathan, H, et al (1998) Oral sildenafil in the treatment of erectile dysfunction N Engl J Med 338,1397-1404[Abstract/Free Full Text]
17. . Center for Drug Evaluation and Research (1998) Phase I investigator-blind, placebo-controlled, evaluation of safety, toleration, and pharmacokinetics of sildenafil following escalation single doses in healthy male volunteers: study 148-004. Animal Pharmacology Viagra (Sildenafil): Joint Clinical Review for NDA-20-895 Center for Drug Evaluation and Research, Food and Drug Administration Washington, DC.
18. Vobig, MA, Klotz, T, Staak, M, Bartz–Schmidt, KU, Engelmann, U, Walter, P. (1999) Retinal side effects of sildenafil (Letter) Lancet 353,375[Medline][Order article via Infotrieve]
19. Kretschmann, U, Gockeln, R, Meschi, M, Stief, CG, Winter, R. (1999) Short time influences of sildenafil on visual function [ARVO Abstracts] Invest Ophthalmol Vis Sci 40,S766Abstract nr 4047.
20. Marmor, M. (1999) Sildenafil (Viagra) and ophthalmology Arch Ophthalmol 117,518-519[Free Full Text]
21. Marmor, M, Kessler, R. (1999) Sildenafil (Viagra) and ophthalmology Surv Ophthalmol 44,153-162[Medline][Order article via Infotrieve]
22. Zrenner, E. (1999) No cause for alarm over retinal side effects of sildenafil [comment] Lancet 353,340-341[Medline][Order article via Infotrieve]
23. Tsang, SH, Gouras, P, Yamashita, CK, et al (1996) Retinal degeneration in mice lacking the subunit of rod cGMP phosphodiesterase Science 272,1026-1029[Abstract]
24. Tsang, SH, Chen, J, Kjeldbye, H, et al (1997) Retarding photoreceptor degeneration in Pdeg^tm1/Pdeg^tm1 mice by an apoptosis suppressor gene Invest Ophthalmol Vis Sci 38,943-950[Abstract/Free Full Text]
25. Tsang, SH, Burns, ME, Calvert, PD, et al (1998) Role for the target enzyme in deactivation of photoreceptor G protein in vivo Science 282,117-121[Abstract/Free Full Text]
26. Salchow, DJ, Gouras, P, Doi, K, Goff, SP, Schwinger, E, Tsang, SH (1999) A point mutation (W70A) in the rod PDE gene desensitizing and delaying murine rod photoreceptors Invest Ophthalmol Vis Sci 40,3262-3267[Abstract/Free Full Text]
27. Cayouette, M, Behn, D, Sendtner, M, Lachapelle, P, Gravel, C. (1998) Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse J Neurosci 18,9282-9293[Abstract/Free Full Text]
28. Peachey, NS, Alexander, KR, Fishman, GA (1987) Rod and cone system contributions to oscillatory potentials: an explanation for the conditioning flash effect Vision Res 27,859-866[Medline][Order article via Infotrieve]
29. Lachapelle, P, Benoit, J, Blain, L, Guite, P, Roy, MS (1990) The oscillatory potentials in response to stimuli of photopic intensities delivered in dark-adaptation: an explanation for the conditioning effect Vision Res 30,503-513[Medline][Order article via Infotrieve]
30. Walker, DK, Ackland, MJ, James, GC, et al (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man Xenobiotica 29,297-310[Medline][Order article via Infotrieve]
31. Wallis, RM, Leishman, D, Pullman, L, Graepel, P, Heywood, R. (1998) Effects of sildenafil on retinal histopathology and electroretinogram (ERG) in dogs (abstract) Ophthalmic Res 30,S68
32. . Centre for Drug Evaluation and Research (1998) Pharmacology: Activities related to mechanism of action: Functional effects on other tissues expressing PDE5 enzyme: Retinal effects. 1.2.3.6, pg 19–21 Viagra (Sildenafil): Joint Clinical Review for NDA-20-895 Center for Drug Evaluation and Research, Food and Drug Administration Washington, DC.
33. Schneider, T, Zrenner, E. (1986) The influence of phosphodiesterase inhibitors on ERG and optic nerve response of the cat Invest Ophthalmol Vis Sci 27,1395-1403[Abstract/Free Full Text]
34. Farber, DB, Lolley, RN (1974) Cyclic guanosine monophosphate: elevation in degenerating photoreceptor cells of the C3H mouse retina Science 186,449-451[Abstract/Free Full Text]
35. Lolley, RN, Farber, DB, Rayborn, ME, Hollyfield, JG (1977) Cyclic GMP accumulation causes degeneration of photoreceptor cells: simulation of an inherited disease Science 196,664-666[Abstract/Free Full Text]
36. Ulshafer, RJ, Garcia, CA, Hollyfield, JG (1980) Sensitivity of photoreceptors to elevated levels of cGMP in the human retina Invest Ophthalmol Vis Sci 19,1236-1241[Abstract/Free Full Text]
37. Boughman, JA, Conneally, PM, Nance, WE (1980) Population genetic studies of retinitis pigmentosa Am J Hum Genet 32,223-235[Medline][Order article via Infotrieve]
38. Berson, EL, Rosen, JB, Simonoff, EA (1979) Electroretinographic testing as an aid in detection of carriers of X-chromosome-linked retinitis pigmentosa Am J Ophthalmol 87,460-468[Medline][Order article via Infotrieve]
39. Laties, AM, Koppiker, NP, Smith, MD (2000) Characterization of visual adverse events after dosing with sildenafil citrate [ARVO Abstracts] Invest Ophthalmol Vis Sci 41,S592Abstract nr 3148.
40. Zrenner, E, Koppiker, NP, Smith, MD, et al (2000) The effects of long-term sildenafil treatment on ocular safety in patients with erectile dysfunction (ED) [ARVO Abstracts] Invest Ophthalmol Vis Sci 41,S592Abstract nr 3147.
41. Phelan, JK, Bok, D. (2000) A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes Mol Vis 6,116-124[Medline][Order article via Infotrieve]
42. Hahn, LB, Berson, EL, Dryja, TP (1994) Evaluation of the gene encoding the gamma subunit of rod phosphodiesterase in retinitis pigmentosa Invest Ophthalmol Vis Sci 35,1077-1082[Abstract/Free Full Text]

This article has been cited by other articles:

				M. B. Jameson, D. M. Sharp, J. I. Sissingh, C. R. Hogg, P. I. Thompson, M. J. McKeage, M. Jeffery, S. Waller, G. Acton, C. Green, et al. Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2553 - 2559. [Abstract] [Full Text] [PDF]

				H. Baquero, A. Soliz, F. Neira, M. E. Venegas, and A. Sola Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study Pediatrics, April 1, 2006; 117(4): 1077 - 1083. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Behn, D. Articles by Potter, M. J. Search for Related Content PubMed PubMed Citation Articles by Behn, D. Articles by Potter, M. J.